NasdaqCM - Nasdaq Real Time Price ? USD Precision BioSciences, Inc. (DTIL) Follow Compare 8.29 -0.73 (-8.09%) At close: November 4 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates Precision BioSciences (DTIL) delivered earnings and revenue surprises of -258.23% and 93.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 22 hours ago DTIL -8.09% Precision BioSciences: Q3 Earnings Snapshot DURHAM, N.C. (AP) — Precision BioSciences Inc. DTIL) on Monday reported a loss of $16.4 million in its third quarter. The Durham, North Carolina-based company said it had a loss of $2.25 per share. Associated Press Finance ? 23 hours ago DTIL -8.09% Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update DURHAM, N.C., November 04, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. Business Wire ? 23 hours ago DTIL -8.09% Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 3 days ago DTIL -8.09% ALEC +4.98% Precision BioSciences to Report Third Quarter Results on November 4, 2024 DURHAM, N.C., October 29, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. Business Wire ? 7 days ago DTIL -8.09% Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 DURHAM, N.C., October 28, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. – 8:30 a.m. PST prior to the American Association for the Study of Liver Diseases (AASLD) Meeting. Business Wire ? 8 days ago DTIL -8.09% Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress DURHAM, N.C., October 24, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress being held October 22-25, 2024, in Rome, Italy. The poster highlighted preclinical data demonstrating the ability of ARCUS to achieve high-efficiency ge Business Wire ? 11 days ago DTIL -8.09% Precision BioSciences to Report Q3 Earnings: What's in the Cards? DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product. Zacks ? 11 days ago DTIL -8.09% PFE NVO Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B DURHAM, N.C., October 24, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Moldova for its lead candidate, PBGENE-HBV. PBGENE-HBV is Precision’s wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key sour Business Wire ? 11 days ago DTIL -8.09% Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences DURHAM, N.C., October 21, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. Business Wire ? 15 days ago DTIL -8.09% Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress DURHAM, N.C., October 16, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for diseases where a defective gene is remedied by expression of a new DNA sequence, today announced a poster presentation at the upcoming European Society of Gene & Cell Therapy (ESGCT) Congress being held October 22-25, 202 Business Wire ? 20 days ago DTIL -8.09% Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Zacks ? last month DTIL -8.09% Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference DURHAM, N.C., October 03, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that the Company will present during a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference taking place October 8, 2024. Business Wire ? last month DTIL -8.09% Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B DURHAM, N.C., September 30, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that the Company submitted Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company’s wholly owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by elimina Business Wire ? last month DTIL -8.09% Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., September 20, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that, on September 18, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Business Wire ? last month DTIL -8.09% Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 277.6% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Zacks ? last month DTIL -8.09% Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution DURHAM, N.C., September 12, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced changes within the Company’s clinical leadership team strengthening its infectious disease and hepatitis capabilities as it prepares to initiate development of its first in vivo gene editing Business Wire ? last month DTIL -8.09% Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock Precision BioSciences (DTIL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. Zacks ? last month DTIL -8.09% Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference DURHAM, N.C., September 04, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that the Company will participate in a panel discussion and fireside chat at the H.C. Wainwright 26th Annual Global Healthcare Conference taking place September 9-11, 2024 in New York. Business Wire ? 2 months ago DTIL -8.09% Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal DURHAM, N.C., September 03, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS? platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced maturity of a $13 million convertible note from its previously announced strategic transaction with Imugene Limited (ASX: IMU) for azercabtagene zapreleucel (azer-cel) in oncology. The proce Business Wire ? 2 months ago DTIL -8.09% Performance Overview Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return DTIL S&P 500 YTD -24.29% +19.77% 1-Year -35.13% +31.07% 3-Year -97.23% +22.57%
